The ON* is on the Employer
By 2008, our economy will have a different look and feel as traditionalists (b. 1925 – 1942) and baby boomers (b. 1943 – 1960) continue to exit the workforce, by choice or not....
By 2008, our economy will have a different look and feel as traditionalists (b. 1925 – 1942) and baby boomers (b. 1943 – 1960) continue to exit the workforce, by choice or not....
The Food and Drug Administration (FDA) recently began requiring applicants to pay significant user fees when filing applications in connection with new medical devices and biologics. Such user fees have long been required for drug-related applications, and now also are required for applications related to...
Spring of ’99 was a great time to start companies, and some wonderful businesses came out of the WAVE Program (Weinert Applied Ventures in Entrepreneurship) at the University of Wisconsin-Madison, including Marsha McVickers’ Errand Solutions and Neil Peters-Michaud’s Cascade Asset Management. As an MBA student,...
Every company that hopes to survive in 2003 has an unambiguous mission statement: “Do more with less, and do it faster!”...
A great perk to traveling – getting to see what the rest of the world is doing. Last week I was in Phoenix vacationing with the family for spring break, content to play a few rounds of golf and see a ballgame, when I was...
Without a doubt, the most common question I’m asked is, “Why won’t angels invest in my business?” While every business is different, two answers apply to 90+% of the entrepreneurs asking this question. The irony is that one answer holds real hope for the vast...
The Food and Drug Administration is changing. However, is it evolving to better serve its customers? I believe the answer is a qualified "yes", but the demands on the agency are growing while its resources are not. The growing demands of scientific discovery, regulatory needs,...
The creation of Wisconsin’s first formal angel networks in 2000 was a watershed, of sorts. Risk capital has a long history here: Venture Investors for “pure” venture capital; Baird and others for late-stage and mezzanine finance;